A finite treatment may reverse one common hormonal cause of hypertension

A Queen Mary-led team followed 14 people at eight U.S. centers who had received an aldosterone synthase inhibitor for 6–12 months for primary aldosteronism. Up to two years after treatment ended, the main marker of excess aldosterone remained 99% below baseline, average blood pressure was 25 points lower and almost one quarter had normal pressure without other medication. The strategy aims to remove abnormal aldosterone-producing cells rather than suppress symptoms for life. The sample is small and based on routine follow-up, so it cannot establish a cure; the larger prospective ELIXIR trial is testing the finding.